Fat Perception in Humans (09-0873) (OT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01128400|
Recruitment Status : Completed
First Posted : May 21, 2010
Results First Posted : July 3, 2014
Last Update Posted : July 3, 2014
There are many substances naturally present in the mouth that may help us taste fat in food. Two of these substances (lipases and CD36) will be examined in this study.
The presence of fat in food increases food tastiness, therefore people often over-eat high-fat foods and gain weight. The purpose of this study is to determine if blocking lipases and some genetic variations in the CD36 gene will make fatty food less tasty so that people eat less. Our hypothesis is that Orlistat and a particular gene will increase one's ability to detect fat.
|Condition or disease|
Determine the effect of lipolysis inhibition in oral cavity on orosensory detection of fat in humans.
Hypothesis: Orally applied Orlistat will increase detection thresholds of TAGs but not FFA in humans.
To test this hypothesis we will measure triolein (a TAG) and oleic acid (a FFA) taste detection thresholds with a three-alternative forced-choice (3-AFC) ascending concentration method under two conditions (Orlistat day vs. Control day). To control for olfactory input, subjects will be assessed wearing noseclips.
- Determine the effect of CD36 variants on fat taste perception in humans. Hypothesis: SNPs that associate with reduced CD36 expression will be associated with higher FFA and TAG detection thresholds
To test this hypothesis we will measure triolein and oleic acid taste detection thresholds in subjects who carry of the common CD36 e-SNP rs1761667 (i.e. a SNP that significantly reduces CD36 level and has a minor allele frequency of 38-48%). We expect subjects who are at least heterozygous for the expression reducing allele to have higher triolein and oleic acid taste detection thresholds compared to non-carrier subjects.
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Observational Model:||Case Control|
|Official Title:||Inhibition of Lipolysis in Oral Cavity and Fat Perception in Humans|
|Study Start Date :||May 2010|
|Primary Completion Date :||June 2014|
|Study Completion Date :||June 2014|
rs1761667- AA genotype
subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
subjects who are homozygous of CD36 genotype rs1761667-G allele.
Heterozygous of CD36 gene rs1761667-A genotype.
- Oleic Acid Detection Level [ Time Frame: Few weeks after screening ]We will measure oleic acid detection levels as a marker of subjects' ability to detect free fatty acids.
- Triolein Detection [ Time Frame: Few weeks after screening ]We will measure triolein detection levels as a marker of subjects' ability to detect triglyceride.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01128400
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63110|
|Principal Investigator:||Marta Y Pepino de Gruev, Ph.D.||Washington University School of Medicine|